- Home
- BRBS vs FULC Comparison
BRBS vs FULC Comparison
Compare BRBS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRBS | FULC |
|---|---|---|
| Founded | 1893 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.3M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BRBS | FULC |
|---|---|---|
| Price | $4.35 | $10.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 220.8K | ★ 1.2M |
| Earning Date | 01-29-2026 | 02-24-2026 |
| Dividend Yield | ★ 5.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $96,332,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $83.34 | ★ N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $2.92 | $2.32 |
| 52 Week High | $4.79 | $15.74 |
Technical Indicators
Market Signals| Indicator | BRBS | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 43.22 |
| Support Level | $4.24 | $9.77 |
| Resistance Level | $4.40 | $10.47 |
| Average True Range (ATR) | 0.12 | 0.69 |
| MACD | -0.01 | -0.30 |
| Stochastic Oscillator | 38.37 | 16.93 |
Price Performance
Historical ComparisonAbout BRBS Blue Ridge Bankshares Inc.
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary, Blue Ridge Bank, National Association, and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance and others. It has three reportable business segments: commercial banking, mortgage banking, and holding company activities.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.